(Q35684127)

9 August 2017

1 reference

title

Novel treatments in non-small cell lung cancer (English)

1 reference

9 August 2017

William T Leslie

1

1 reference

PubMed ID

15005292

9 August 2017

Philip D Bonomi

series ordinal

2

1 reference

9 August 2017

1 February 2004

1 reference

Hematology / Oncology Clinics of North America

9 August 2017

1 reference

9 August 2017

18

1 reference

9 August 2017

1

1 reference

9 August 2017

245-267

1 reference

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Novel targets for lung cancer therapy: part I.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Novel targets for lung cancer therapy: part II.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Expression Cloning of Human EGF Receptor Complementary DNA: Gene Amplification and Three Related Messenger RNA Products in A431 Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

ErbB-targeted therapeutic approaches in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Studies with ZD1839 in preclinical models

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Herceptest: HER2 expression and gene amplification in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Angiogenesis as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Angiogenesis inhibitors in clinical development for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Changing views of the role of matrix metalloproteinases in metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Development of matrix metalloproteinase inhibitors in cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Expression and Prognostic Significance of Metalloproteinases and Their Tissue Inhibitors in Patients With Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Protein kinase C targeting in antineoplastic treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

The retinoid signaling pathway: molecular and genetic analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Activation of retinoid X receptors induces apoptosis in HL-60 cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Blocking oncogenic Ras signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Cyclooxygenase-2: A Target for Chemoprevention and Treatment of Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Role of Cyclooxygenase-2 Inhibitors in Combination with Radiation Therapy in Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

p53, the cellular gatekeeper for growth and division

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

p53 is required for radiation-induced apoptosis in mouse thymocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

p53-independent apoptosis induced by paclitaxel through an indirect mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Histone deacetylases and cancer: causes and therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Improving the evaluation of new cancer treatments: challenges and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900146-1

7 January 2021

10.1016/S0889-8588(03)00146-1

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

15005292